Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angi...
- Autores:
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13162
- Acceso en línea:
- https://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#!
http://hdl.handle.net/20.500.12010/13162
https://doi.org/10.1016/j.pharmthera.2020.107628
- Palabra clave:
- RAAS inhibitors
Hypertension
Bradykinin
Inflammation
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Acceso restringido